drugset / Trial / NCT01069796
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).
Timeline
- Start
- 2010-04
- Primary completion
- 2012-03
- Completion
- 2014-06
Outcome
Outcome not reported
Stopped: “The number of inclusion was reached normally”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 800 mg/m2 | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |